Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China · Delayed Price · Currency is CNY 39.42
-0.59 (-1.47%)
Jan 22, 2026, 3:00 PM CST
SHA:688062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 624.36 | 199.62 | 127.68 | 27.6 | 15.88 | 5.16 | Upgrade |
Other Revenue | 0.16 | 0.16 | 0.15 | 0.13 | 0.35 | 0.14 | Upgrade |
| 624.52 | 199.78 | 127.84 | 27.73 | 16.23 | 5.3 | Upgrade | |
Revenue Growth (YoY) | 268.63% | 56.28% | 361.03% | 70.88% | 206.03% | -81.98% | Upgrade |
Cost of Revenue | 62.61 | 34.48 | 7.3 | 2.01 | 5.22 | 5.4 | Upgrade |
Gross Profit | 561.91 | 165.3 | 120.53 | 25.72 | 11 | -0.1 | Upgrade |
Selling, General & Admin | 423.34 | 405.2 | 368.36 | 267.62 | 189.16 | 87.08 | Upgrade |
Research & Development | 1,014 | 782.87 | 835.78 | 758.61 | 622.51 | 581.19 | Upgrade |
Other Operating Expenses | 3.55 | 4.42 | 3.8 | 1.88 | 0.8 | 0.93 | Upgrade |
Operating Expenses | 1,440 | 1,193 | 1,208 | 1,028 | 812.44 | 668.06 | Upgrade |
Operating Income | -878.35 | -1,027 | -1,087 | -1,002 | -801.44 | -668.16 | Upgrade |
Interest Expense | -80.31 | -57.78 | -13.35 | -10.3 | -6.41 | -1.04 | Upgrade |
Interest & Investment Income | 8.89 | 20.92 | 46.88 | 45.75 | 7.38 | 16.87 | Upgrade |
Currency Exchange Gain (Loss) | 0.28 | 0.28 | -0.01 | 0.16 | -0.24 | -0.08 | Upgrade |
Other Non Operating Income (Expenses) | -1.35 | -2.34 | -1.74 | -1.82 | 2.63 | -2.94 | Upgrade |
EBT Excluding Unusual Items | -950.83 | -1,066 | -1,056 | -968.59 | -798.07 | -655.35 | Upgrade |
Gain (Loss) on Sale of Investments | -6.71 | -3.73 | -4.69 | 1.08 | -0.23 | 1.09 | Upgrade |
Gain (Loss) on Sale of Assets | -0.12 | -0.11 | -0.01 | 0.33 | 2.06 | -0.01 | Upgrade |
Asset Writedown | -1.14 | - | -3.56 | - | - | - | Upgrade |
Other Unusual Items | 22.77 | 22.5 | 8.61 | 9.06 | 23.54 | 10.65 | Upgrade |
Pretax Income | -936.04 | -1,047 | -1,055 | -958.13 | -772.7 | -643.62 | Upgrade |
Income Tax Expense | 14.11 | -0.91 | 3.52 | - | - | - | Upgrade |
Earnings From Continuing Operations | -950.15 | -1,047 | -1,059 | -958.13 | -772.7 | -643.62 | Upgrade |
Minority Interest in Earnings | 2.66 | 2.65 | 5.38 | 2.89 | 3.11 | 1.08 | Upgrade |
Net Income | -947.49 | -1,044 | -1,053 | -955.23 | -769.59 | -642.55 | Upgrade |
Net Income to Common | -947.49 | -1,044 | -1,053 | -955.23 | -769.59 | -642.55 | Upgrade |
Shares Outstanding (Basic) | 400 | 400 | 399 | 391 | 299 | 284 | Upgrade |
Shares Outstanding (Diluted) | 400 | 400 | 399 | 391 | 299 | 284 | Upgrade |
Shares Change (YoY) | 0.50% | 0.24% | 1.93% | 30.74% | 5.32% | - | Upgrade |
EPS (Basic) | -2.37 | -2.61 | -2.64 | -2.44 | -2.57 | -2.26 | Upgrade |
EPS (Diluted) | -2.37 | -2.61 | -2.64 | -2.44 | -2.57 | -2.26 | Upgrade |
Free Cash Flow | -626.14 | -1,287 | -1,283 | -1,264 | -639.91 | -645.61 | Upgrade |
Free Cash Flow Per Share | -1.57 | -3.22 | -3.21 | -3.23 | -2.14 | -2.27 | Upgrade |
Gross Margin | 89.97% | 82.74% | 94.29% | 92.75% | 67.81% | -1.87% | Upgrade |
Operating Margin | -140.64% | -514.17% | -850.65% | -3615.06% | -4939.16% | -12601.66% | Upgrade |
Profit Margin | -151.71% | -522.53% | -824.05% | -3445.00% | -4742.85% | -12118.54% | Upgrade |
Free Cash Flow Margin | -100.26% | -643.96% | -1003.35% | -4559.01% | -3943.69% | -12176.27% | Upgrade |
EBITDA | -764.68 | -930.36 | -1,013 | -937.96 | -739.4 | -611.77 | Upgrade |
D&A For EBITDA | 113.67 | 96.85 | 74.43 | 64.43 | 62.04 | 56.39 | Upgrade |
EBIT | -878.35 | -1,027 | -1,087 | -1,002 | -801.44 | -668.16 | Upgrade |
Revenue as Reported | 624.52 | 199.78 | 127.84 | 27.73 | 16.23 | 5.3 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.